RLMD logo

RLMD
Relmada Therapeutics Inc

2,129
Mkt Cap
$798.21M
Volume
1.76M
52W High
$7.94
52W Low
$0.2675
PE Ratio
-4.96
RLMD Fundamentals
Price
$7.29
Prev Close
$7.61
Open
$7.72
50D MA
$5.31
Beta
0.53
Avg. Volume
3.21M
EPS (Annual)
-$1.45
P/B
6.18
Rev/Employee
$0.00
$97.68
Loading...
Loading...
News
all
press releases
Relmada Therapeutics (NASDAQ:RLMD) Hits New 12-Month High - Should You Buy?
Relmada Therapeutics (NASDAQ:RLMD) Sets New 12-Month High - Here's What Happened...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics
Small drug stocks like Indivior gain traction as biotech recovery strengthens, fueled by innovation, M&A activity, and promising pipeline developments.
Zacks·5d ago
News Placeholder
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, CPRX, TBPH, RLMD and AVTX may prove to be good additions to one's portfolio.
Zacks·9d ago
News Placeholder
Wall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should Know
The mean of analysts' price targets for Relmada Therapeutics (RLMD) points to a 92.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·16d ago
News Placeholder
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Large Increase in Short Interest
Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) was the target of a large increase in short interest in March. As of March 13th, there was short interest totaling 3,731,201 shares, an...
MarketBeat·17d ago
News Placeholder
Relmada Therapeutics (NASDAQ:RLMD) Earns Overweight Rating from Analysts at Piper Sandler
Piper Sandler started coverage on Relmada Therapeutics in a research note on Tuesday. They set an "overweight" rating and a $12.00 price objective for the company...
MarketBeat·18d ago
News Placeholder
Relmada Therapeutics (NASDAQ:RLMD) Price Target Raised to $19.00
Mizuho raised their target price on Relmada Therapeutics from $10.00 to $19.00 and gave the stock an "outperform" rating in a research note on Friday...
MarketBeat·22d ago
News Placeholder
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Consensus Rating of "Moderate Buy" from Brokerages
Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) has been given an average rating of "Moderate Buy" by the six research firms that are presently covering the firm, MarketBeat.com reports...
MarketBeat·22d ago
News Placeholder
Relmada Therapeutics (NASDAQ:RLMD) Releases Quarterly Earnings Results, Misses Estimates By $0.15 EPS
Relmada Therapeutics (NASDAQ:RLMD - Get Free Report) posted its earnings results on Thursday. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.15...
MarketBeat·22d ago
News Placeholder
Relmada Therapeutics Q4 Earnings Call Highlights
Relmada Therapeutics (NASDAQ:RLMD) outlined progress on its lead urology oncology program and reviewed fourth-quarter results during its fourth quarter and full year 2025 earnings call, highlighting durable Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC), plans to begin a Phase...
MarketBeat·22d ago
<
1
2
...
>

Latest RLMD News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.